Intradiscal Methylene Blue Injection for Discogenic Low Back Pain: A Meta-Analysis (2018)

Peer-Reviewed Study · Guo X, Ding W, Liu L, et al. · August 30, 2018

Guo X et al., 2018-08-30: Meta-analysis of five studies (mostly before-after) reporting pain and disability improvement after intradiscal methylene blue, with a call for larger studies. Weaker design than the RCT meta-analysis.

Intradiscal MB injection can reduce pain severity and improve the ODI score in individuals with discogenic low back pain. Although intradiscal MB injection seems to be a safe and effective treatment for discogenic low back pain, the clinical benefits for patients with discogenic low back pain need to be further appraised in larger samples and more in-depth studies.

Guo X et al., 2018-08-30: Meta-analysis of five studies (mostly before-after) reporting pain and disability improvement after intradiscal methylene blue, with a call for larger studies. Weaker design than the RCT meta-analysis. Study type: systematic review and meta-analysis. N=5 studies, English-language only, to October 2017. Countries: China, Korea, Netherlands. Intradiscal MB. Funding/conflicts: not stated. Comparator: pre-operative vs post-operative within studies (not all placebo-controlled). Bearing SUPPORTS but the pooling of uncontrolled before-after data overstates the evidence. Study type: review.